Carla Vozone, Hovione's Senior Director of Product Development and Licensing is delighted that Hovione's science in inhalation development and manufacturing is the conduit for Invion's INV104 program.
"Hovione has built through the years a profound and unique skill set in APIs, particle engineering, formulation and devices, being able to approach inhalation development holistically. Hovione's ability to manufacture all components of the drug product in the same location and solve problems within the same team accelerates development," she said. Carla Vozone recognized that the co- development partnership entered with Invion illustrates Hovione's goal of repurposing drugs trough alternative delivery routes with the aim of increasing its safety profile and patient compliance.
"Aligning Hovione's knowledge in inhalation with Invion's clinical expertise builds synergies for a winning proposition," she said. http://www.kcentv.com/story/2963778...d-licensing-agreement-for-inhaled-zafirlukast
IVX is still very much a specky and dovetree may very well be a troll but I have seen the predictions and opinions of many trolls on this website come through as they may be more objective with their views.
For those who know IVX well what do you think is the Short Term potential in regards to the share price. And full potential ??
Wishing all the investors here all the best.
IVX Price at posting:
2.6¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)